| [1] |
Sakhuja A, Kumar G, Gupta S, et al. Acute kidney injury requiring dialysis in severe sepsis[J]. Am J Respir Crit Care Med, 2015, 192(8): 951–957.
|
| [2] |
Tam VH, Schilling AN, Neshat S, et al. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa[J]. Antimicrob Agents Chemother, 2005, 49(12): 4920–4927.
|
| [3] |
Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men[J]. Clin Infect Dis, 1998, 26(1): 1–10.
|
| [4] |
Louie A, Kaw P, Liu W, et al. Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection[J]. Antimicrob Agents Chemother, 2001, 45(3): 845–851.
|
| [5] |
Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists[J]. Clin Infect Dis, 2009, 49(3): 325–327.
|
| [6] |
Stein GE, Craig WA. Tigecycline: a critical analysis[J]. Clin Infect Dis, 2006, 43(4): 518–524.
|
| [7] |
Roberts DM. The relevance of drug clearance to antibiotic dosing in critically ill patients[J]. Curr Pharm Biotechnol, 2011, 12(12): 2002–2014.
|
| [8] |
Blot S, Lipman J, Roberts DM, et al. The influence of acute kidney injury on antimicrobial dosing in critically ill patients: are dose reductions always necessary[J]. Diagn Microbiol Infect Dis, 2014, 79(1): 77–84.
|
| [9] |
Choi G, Gomersall CD, Tian Q, et al. Principles of antibacterial dosing in continuous renal replacement therapy[J]. Crit Care Med, 2009, 37(7): 2268–2282.
|
| [10] |
Wong WT, Choi G, Gomersall CD, et al. To increase or decrease dosage of antimicrobials in septic patients during continuous renal replacement therapy: the eternal doubt[J]. Curr Opin Pharmacol, 2015, 24(1): 68–78.
|
| [11] |
Mueller BA, Scarim SK, Macias WL. Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treatedwith continuous hemofiltration[J]. Am J Kidney Dis, 1993, 21(2): 172–179.
|
| [12] |
Ververs TF, van Dijk A, Vinks SA, et al. Pharmacokinetics and dosing regimen ofmeropenem in critically ill patients receiving continuous venovenoushemofiltration[J]. Crit Care Med, 2000, 28(10): 3412–3416.
|
| [13] |
Longo C, Bartlett G, Macgibbon B, et al. The effect of obesity on antibiotic treatmentfailure: a historical cohort study[J]. Pharmacoepidemiol Drug, 2013, 22(9): 970–976.
|
| [14] |
Kielstein JT, Burkhardt O. Dosing of antibiotics in critically illpatients undergoing renal replacement therapy[J]. Curr Pharm Biotechnol, 2011, 12(12): 2015–2019.
|
| [15] |
Kielstein JT, David S. Pro: renal replacement trauma or Paracelsus 2.0[J]. Nephrol Dial Transplant, 2013, 28(11): 2728–2733.
|
| [16] |
Li AMMY, Gomersall CD, Choi G, et al. A systematic review of antibiotic dosing regimens for septic patients receiving continuous renal replacement therapy: do current studies supply sufficient data[J]. J Antimicrob Chemother, 2009, 64(5): 929–937.
|
| [17] |
Valtonen M, Tiula E, Takkunem O, et al. Elimination of piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodialfiltration in patients with acute renal failure[J]. J Antimicrob Chemother, 2001, 48(6): 881–885.
|
| [18] |
Mueller BA, Scarim SK, Macias WL. Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration[J]. Am J Kidney Dis, 1993, 21(2): 172–179.
|
| [19] |
Dulhunty JM, Roberts JA, Davis JS, et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial[J]. Clin Infect Dis, 2013, 56(2): 236–244.
|
| [20] |
Isla A, Gascon AR, Maynar J, et al. In vitro AN69 and poly sulphone membrane permeability to ceftazidime and in vivo pharmacokinetics during continuous renal replacement therapies[J]. Chemotherapy, 2007, 53(3): 194–201.
|
| [21] |
Mariat C, Venet C, Jehl F, et al. Continuous infusion of ceftazidime in critically ill patients undergoing continuous veno-venous haemodiafiltration: pharmacokinetic evaluation and dose recommendation[J]. Crit Care, 2006, 10(1): R26.
|
| [22] |
Allaouchiche B, Breilh D, Jaumain H, et al. Pharmacokinetics ofcefepime during continuous venovenous hemodiafiltration[J]. Antimicrob Agents Chemother, 1997, 41(11): 2424–2427.
|
| [23] |
Bellmann R, Falkensammer G, Seger C, et al. Teicoplanin pharmacokinetics in critically ill patients on continuous veno-venous hemofiltration[J]. Int J Clin Pharmacol Ther, 2010, 48(4): 243–249.
|
| [24] |
Seyler L, Cotton F, Taccone FS, et al. Recommended beta-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy[J]. Crit Care, 2011, 15(3): R137.
|
| [25] |
Ververs TF, van Dijk A, Vinks SA, et al. Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration[J]. Crit Care Med, 2000, 28(10): 3412–3416.
|
| [26] |
Krueger WA, Schroeder TH, Hutchison M, et al. Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration[J]. Antimicrob Agents Chemother, 1998, 42(9): 2421–2424.
|
| [27] |
Krueger WA, Neeser G, Schuster H, et al. Correlation of meropenem plasma levelswith pharmacodynamic requirements incritically ill patients receiving continuous veno-venous hemofiltration[J]. Chemotherapy, 2003, 49(6): 280–286.
|
| [28] |
Mueller BA, Scarim SK, Macias WL. Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration[J]. Am J Kidney Dis, 1993, 21(2): 172–179.
|
| [29] |
Akers KS, Cota JM, Frei CR, et al. Once-daily amikacin dosing in burn patients treated with continuous venovenous hemofiltration[J]. Antimicrob Agents Chemother, 2011, 55(10): 4639–4642.
|
| [30] |
D′Arcy DM, Casey E, Gowing CM, et al. An open prospective study ofamikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration[J]. BMC Pharmacol Toxicol, 2012, 13(1): 14–17.
|
| [31] |
Petejova N, Zahalkova J, Duricova J, et al. Gentamicin pharmacokinetics during continuous venovenous hemofiltration in critically ill septic patients[J]. J Chemother, 2012, 24(2): 107–112.
|
| [32] |
Taccone FS, de Backer D, Laterre PF, et al. Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy[J]. Int J Antimicrob Agents, 2011, 37(6): 531–535.
|
| [33] |
Udy AA, Roberts JA, Boots RJ, et al. Augmented renal clearance: implications for antibacterial dosing in the critically ill[J]. Clin Pharmacokinet, 2010, 49(1): 1–16.
|
| [34] |
Del Dot ME, Lipman J, Tett SE. Vancomycin pharmacokinetics in critically ill patients receiving continuous hemodialfiltration[J]. Br J Clin Pharmacol, 2004, 58(3): 259–268.
|
| [35] |
Boereboom FT, Ververs FF, Blankestijn PJ, et al. Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients[J]. Intensive Care Med, 1999, 25(10): 1100–1104.
|
| [36] |
Santre C, Leroy O, Simon M, et al. Pharmacokinetics of vancomycin during continuous hemodialfiltration[J]. Intensive Care Med, 1993, 19(6): 347–350.
|
| [37] |
Honore PM, Jacobs R, Joannes-Boyau O, et al. Continuousrenal replacement therapy-related strategies to avoid colistin toxicity: a clinically orientated review[J]. Blood Purif, 2014, 37(4): 291–295.
|
| [38] |
Petejova N, Martinek A, Zahalkova J, et al. Vancomy cinremoval during low-flux and high-flux extended daily hemodialysis in critically ill septic patients[J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2012, 156(4): 342–347.
|
| [39] |
Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin[J]. Antimicrob Agents Chemother, 2004, 48(1): 63–68.
|
| [40] |
Khadzhynov D, Slowinski T, Lieker I, et al. Plasma pharmacokinetics of daptomycin in critically ill patients with renal failure and under going CVVHD[J]. Int J Clin Pharmacol Ther, 2011, 49(11): 656–665.
|
| [41] |
Andes D, van Ogtrop ML, Peng J, et al. In vivo pharmacodynamics of a new oxazolidinone (linezolid)[J]. Antimicrob Agents Chemother, 2002, 46(11): 3484–3489.
|
| [42] |
Jamal JA, Mueller BA, Choi G, et al. How can we ensure effective antibiotic dosing in critically ill patients receiving different types of renal replacement therapy[J]. Diagn Microbiol Infect Dis, 2015, 82(1): 92–103.
|